Ignite Creation Date:
2024-05-05 @ 10:00 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00000958
Status:
COMPLETED
Last Update Posted:
2021-11-04
First Post:
1999-11-02
Brief Title:
A Placebo-Controlled Phase I Pilot Clinical Trial to Evaluate the Safety and Immunogenicity of ENV 2-3 a Yeast-Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1 in Combination With MTP-PEMF59 in Individuals With HIV Infection Placebo Patients Receive MF59 Emulsion Only
Sponsor:
Organization:
National Institute of Allergy and Infectious Diseases NIAID